Saadvik Raghuram Y, Head of Department of Medical Oncology at Arete Hospitals, shared a post on X:
“FDA approves Talectrectinib for ROS1-positive locally advanced or metastatic NSCLC.
Response rates in TKI naive (85-90%)
ORR in patients with prior TKI (52%)
CNS response rates in TKI Naive (73%), prior TKI (63%)
Watch out for Dizziness, QTc”
More posts featuring Saadvik Raghuram Y on OncoDaily.